A forum for researchers, students and applicants in the field of cyclodextrin technology
Approval based on results from three pivotal trials showing treatment with ZULRESSO provided significant and rapid reduction of depressive symptoms
As of January 1st, 2019, besides the long valid (August 1st, 2012) monograph in USP NF for Betadex Sulfobutyl Ether
A recent paper in Cell Reports published an interesting finding: polymeric degradation products (compound X and Z, respectively) of antibiotics
National Medical Products Administration Approves Melphalan Hydrochloride For Injection (EVOMELA®, formulation based on SBECD aka. Captisol or Dexolve) as Treatment
If approved, ZULRESSO would be the first medicine specifically indicated for the treatment of postpartum depression (PPD) Sage Therapeutics (NASDAQ:
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, announced positive
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company devoted to development of next-generation medicines to improve the lives of
Melinta Therapeutics, Inc. (NASDAQ: MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, delivered eight
Amgen (NASDAQ:AMGN) recently announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA)
There is a not extremely recent but certainly very interesting patent application related to a special use of cyclodextrins, namely
